Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MRSA Infections Add 190 Billion Yen Annually to Medical Expenditure at DPC Hospitals: MHLW Study Group
July 25, 2016
- MHLW Advisory Panel to Discuss Novartis’s Acromegaly Drug on August 4
July 22, 2016
- MHLW Panel OKs Basic Policies for Next JP Edition, Due Out 2021
July 21, 2016
- ICH Guidelines on Multi-Regional Clinical Trials Up for Public Comments: MHLW
July 21, 2016
- Ono Issues Red Flag over Use of Immunotherapies Together with Opdivo
July 21, 2016
- PMDA to Announce Evaluation Policy on Diagnosis Using Next-Generation Sequencers
July 21, 2016
- PMDA Working Group to “Feed Back Experiences in Reviews” toward Creation of Clinical Innovation Network
July 20, 2016
- 14-Day Prescription Limit Won’t Be Eased: MHLW
July 19, 2016
- Zyprexa under PMDA Review for Risk of Drug-Induced Hypersensitivity Syndrome
July 19, 2016
- CDISC Therapeutic Area Standards “Can Be Used in Japan”: MHLW Study Group
July 19, 2016
- Generics Should Vie on “Quality and Attractiveness”: MHLW Pharma Bureau Chief
July 15, 2016
- MHLW Pharma Bureau Chief Wants to Discuss Roles of Drug Makers’ 3 Key Officers
July 15, 2016
- Certified Review Boards Will Be Required “at Around 50 Institutions” if Clinical Research Bill Passes: MHLW Director
July 15, 2016
- MHLW to Request Budgets for AMED’s Project to Promote Commercialization of Innovative Medical Seeds
July 15, 2016
- More Companies Interested in Supporting Academia Research from the Seeds Stage: AMED Official
July 14, 2016
- MHLW to Set Prerequisites for Patients, Physicians to Optimize Innovative Drug Use: Pharma Bureau Chief
July 13, 2016
- Despite Brexit, Importance of UK “Will Remain Unchanged”: Dr Suematsu of AMED
July 12, 2016
- AMED Aims to Facilitate Drug Makers’ Access to Knowledge at Research Institutions: President
July 12, 2016
- PMDA Inks Comprehensive Collaboration Accord with NCNP
July 12, 2016
- MHLW to Put Expensive Drug Issue Up for Chuikyo Discussion ASAP: Medical Economics Division Chief
July 11, 2016
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…